Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novartis (SWX:NOVN) has recorded its 29th consecutive annual dividend increase, extending a nearly three decade payout track record.
The company reports reaching key operational and financial milestones earlier than planned, including margin related targets.
Novartis highlights growth in its cell and gene therapy business, with Zolgensma sales and related pipeline programs progressing.
For you as an investor, this mix of long running dividend consistency and earlier than expected operational milestones presents Novartis as a large cap pharmaceutical group with both income and growth angles. The company is active across prescription medicines and is putting particular emphasis on cell and gene therapies, an area that many see as an important part of future drug development.
The recent update on Zolgensma and the broader pipeline indicates that Novartis is aiming to build a stronger foothold in that segment while still keeping cash returns to shareholders on the agenda. As you assess SWX:NOVN, the balance between its established portfolio, dividend policy, and higher risk cell and gene therapy projects may be a key consideration.
Stay updated on the most important news stories for Novartis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novartis.
SWX:NOVN Earnings & Revenue Growth as at Feb 2026
How Novartis stacks up against its biggest competitors
The latest update paints a picture of a company leaning into higher risk, higher complexity areas like cell and gene therapy while still keeping shareholder payouts front and center. The proposed 5.7% dividend lift to CHF 3.70 per share and early delivery of the 40% core margin target suggest Novartis is using cost discipline and product-mix shifts to support cash returns as it builds out therapies such as Zolgensma, in a market where peers like Roche and Pfizer are also pushing into advanced treatments.
The news lines up with existing investor narratives that focus on late stage autoimmune assets, US manufacturing build out and capital allocation. Progress in cell and gene therapy, the Avidity Biosciences deal pipeline and a long running dividend track record all sit alongside guidance for low single digit net sales growth and a low single digit decline in core operating income in 2026, which reflects the tension between funding future therapies and managing loss of exclusivity on legacy drugs.
Long running dividend increases and a 2025 proposal of CHF 3.70 per share can appeal if you focus on income stability from a large cap pharma name.
Growth in cancer and gene therapy assets such as Kisqali, Kesimpta, Scemblix, Pluvicto and Zolgensma may help offset pressure from generic competitors over time.
Management expects 2026 core operating income to decline low single digit, and guidance already reflects competition from cheaper copies of products like Entresto.
Analysts have flagged pricing pressure, loss of exclusivity and execution risk on acquisitions and advanced manufacturing as key watch points for future returns.
From here, you may want to track how quickly newer therapies ramp, how the Avidity acquisition and other deals are integrated, and whether margins hold up as generic competition and pricing pressure build. If you want to see how different investors are joining the dots between these updates and the longer term story, take a look at the community narratives for Novartis on the dedicated company page by checking the community narratives and fair value views that other investors are using.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com